#BEGIN_DRUGCARD DB01232

# AHFS_Codes:
08:18.08.08

# ATC_Codes:
J05AE01

# Absorption:
Absolute bioavailability averages 4%

# Biotransformation:
Hepatic

# Brand_Mixtures:
Not Available

# Brand_Names:
Fortovase
Invirase
ROC

# CAS_Registry_Number:
127779-20-8

# ChEBI_ID:
Not Available

# Chemical_Formula:
C38H50N6O5

# Chemical_IUPAC_Name:
(2S)-N-[(2S,3R)-4-[(3S)-3-(tert-butylcarbamoyl)-decahydroisoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinolin-2-ylformamido)butanediamide

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2239083

# Description:
An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases. [PubChem]

# Dosage_Forms:
Capsule	Oral
Tablet	Oral

# Drug_Category:
Anti-HIV Agents
HIV Protease Inhibitors

# Drug_Interactions:
Abacavir	The serum concentration of Abacavir may be decreased by protease inhibitors such as Saquinavir. The antiviral response should be closely monitored.
Abiraterone 	Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely.
Alprazolam	The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, alprazolam.
Amiodarone	The protease inhibitor, saquinavir, may increase the effect and toxicity of amiodarone.
Artemether	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
Asenapine	Increased incidence of adverse effects due to pharmacodynamic synergism. Concomitant therapy should be avoided.
Astemizole	Increased risk of cardiotoxicity and arrhythmias
Atorvastatin	Saquinavir may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if saquinavir is initiated, discontinued or dose changed.
Bromazepam	Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if saquinavir is initiated, discontinued or dose changed. Dosage adjustments may be required.
Cabazitaxel	Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy.
Chlordiazepoxide	The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, chlordiazepoxide.
Cisapride	Increased risk of cardiotoxicity and arrhythmias
Clonazepam	The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, clonazepam.
Clorazepate	The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, clorazepate.
Cyclosporine	The protease inhibitor, saquinavir, may increase the effect of cyclosporine.
Dantrolene	Saquinavir may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if saquinavir is initiated, discontinued or dose changed.
Darunavir	Decreased levels of darunavir
Delavirdine	Increases the effect of saquinavir and hepatic toxicity
Diazepam	The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, diazepam.
Dihydroergotamine	The protease inhibitor, saquinavir, may increase the effect and toxicity of the ergot derivative, dihydroergotamine.
Efavirenz	Efavirenz decreases the effect of saquinavir
Eplerenone	This CYP3A4 inhibitor increases the effect and toxicity of eplerenone
Ergotamine	The protease inhibitor, saquinavir, may increase the effect and toxicity of the ergot derivative, ergotamine.
Erlotinib	This CYP3A4 inhibitor increases levels/toxicity of erlotinib
Estazolam	The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, estazolam.
Etravirine	Etravirine, when used concomitantly with protease inhibitors, may experience a decrease in serum concentration. 

Protease inhibitors, when used concomitantly with etravirine, may experience an increase in serum concentration. 

Ritonavir boosting of etravirine therapy is a requirement to concurrent therapy. In addition, it is recommended to monitor serum concentrations of the antiretrovirals, as well as to monitor antiretroviral therapy for efficacy.
Fentanyl	The protease inhibitor, saquinavir, may increase the effect and toxicity of fentanyl.
Flurazepam	The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, flurazepam.
Fusidic Acid	The protease inhibitor, saquinavir, may increase the effect and toxicity of fusidic acid.
Indinavir	Possible antagonism of action
Ketoconazole	Ketoconazole may increase the effect and toxicity of saquinavir.
Lovastatin	Saquinavir may increase the effect and toxicity of lovastatin. Concomitant therapy is contraindicated.
Midazolam	The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, midazolam.
Nevirapine	Decreases the effect of saquinavir
Pazopanib	Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy.
Pimozide	The protease inhibitor, saquinavir, may increase the effect and toxicity of pimozide.
Ponatinib 	Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
Ranolazine	Increased levels of ranolazine - risk of toxicity
Rifabutin	Rifabutin decreases the effect of saquinavir
Rifampin	Rifampin decreases the effect of saquinavir
Tacrolimus	The protease inhibitor, Saquinavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Saquinavir therapy is initiated, discontinued or altered.
Tadalafil	Saquinavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
Tamoxifen	Saquinavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen.
Tamsulosin	Saquinavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Saquinavir is initiated, discontinued, or dose changed.
Telavancin	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
Telithromycin	Saquinavir may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
Temsirolimus	Saquinavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
Teniposide	The strong CYP3A4 inhibitor, Saquinavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Saquinavir is initiated, discontinued or dose changed.
Terfenadine	Increased risk of cardiotoxicity and arrhythmias
Tiagabine	The strong CYP3A4 inhibitor, Saquinavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Saquinavir is initiated, discontinued or dose changed.
Tipranavir	Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Saquinavir. Consider alternate therapy.
Tolterodine	Saquinavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
Tolvaptan	Saquinavir is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan.
Topotecan	The p-glycoprotein inhibitor, Saquinavir, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
Tramadol	Saquinavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
Trazodone	The protease inhibitor, Saquinavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Saquinavir is initiated, discontinued or dose changed.
Triazolam	The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, triazolam.
Trimipramine	The strong CYP3A4 inhibitor, Saquinavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Saquinavir is initiated, discontinued or dose changed.
Vardenafil	Saquinavir, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
Vemurafenib	Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely.
Venlafaxine	Saquinavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Saquinavir is initiated, discontinued, or dose changed.
Verapamil	Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Saquinavir is initiated, discontinued or dose changed.
Vinblastine	Saquinavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Saquinavir is initiated, discontinued or dose changed.
Vincristine	Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Saquinavir is initiated, discontinued or dose changed.
Vinorelbine	Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Saquinavir is initiated, discontinued or dose changed.
Voriconazole	Voriconazole may increase the serum concentration of saquinavir by decreasing its metabolism. Saquinavir may increase the serum concentration of voriconazole. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed.
Zolpidem	Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if saquinavir is initiated, discontinued or dose changed.
Zonisamide	Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if saquinavir is initiated, discontinued or dose changed.
Zopiclone	Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if saquinavir is initiated, discontinued or dose changed.

# Drug_Reference:
11483925	Forestier F, de Renty P, Peytavin G, Dohin E, Farinotti R, Mandelbrot L: Maternal-fetal transfer of saquinavir studied in the ex vivo placental perfusion model. Am J Obstet Gynecol. 2001 Jul;185(1):178-81.

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
-6.26

# Experimental_LogP_Hydrophobicity:
3.8

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Insoluble

# Food_Interactions:
Take after a full meal.

# GenBank_ID:
Not Available

# Generic_Name:
Saquinavir

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C38H50N6O5/c1-38(2,3)43-37(49)32-20-26-14-7-8-15-27(26)22-44(32)23-33(45)30(19-24-11-5-4-6-12-24)41-36(48)31(21-34(39)46)42-35(47)29-18-17-25-13-9-10-16-28(25)40-29/h4-6,9-13,16-18,26-27,30-33,45H,7-8,14-15,19-23H2,1-3H3,(H2,39,46)(H,41,48)(H,42,47)(H,43,49)/t26?,27?,30-,31-,32-,33+/m0/s1

# InChI_Key:
InChIKey=QWAXKHKRTORLEM-LINFGICFSA-N

# Indication:
For the treatment of HIV-1 with advanced immunodeficiency together with antiretroviral nucleoside analogues.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D00429

# LIMS_Drug_ID:
1232

# Mechanism_Of_Action:
Saquinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.

# Melting_Point:
349.84 Â°C

# Molecular_Weight_Avg:
670.8408

# Molecular_Weight_Mono:
670.38426874

# Organisms_Affected:
Human Immunodeficiency Virus

# PDB_Experimental_ID:
1ODW

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA451305

# Pharmacology:
Saquinavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Saquinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.

# Predicted_LogP_Hydrophobicity:
4.04

# Predicted_LogS:
-5.4

# Predicted_Water_Solubility:
2.47e-03 g/l

# Primary_Accession_No:
DB01232

# Protein_Binding:
98%

# PubChem_Compound_ID:
60787

# PubChem_Substance_ID:
46508726

# RxList_Link:
http://www.rxlist.com/cgi/generic/saquin.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00623

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC(C)(C)NC(=O)[C@@H]1CC2CCCCC2CN1C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC2=CC=CC=C2C=C1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
SQV
Saquinavir Mesylate

# Synthesis_Reference:
Not Available

# Toxicity:
Probably experience pain in the throat

# Update_Date:
2013-02-08 16:20:01 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Saquinavir

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP3A5

# Phase_1_Metabolizing_Enzyme_1_ID:
4118

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 3A5

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 3A5
MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNVLSYRQGLWKF
DTECYKKYGKMWGTYEGQLPVLAITDPDVIRTVLVKECYSVFTNRRSLGPVGFMKSAISL
AEDEEWKRIRSLLSPTFTSGKLKEMFPIIAQYGDVLVRNLRREAEKGKPVTLKDIFGAYS
MDVITGTSFGVNIDSLNNPQDPFVESTKKFLKFGFLDPLFLSIILFPFLTPVFEALNVSL
FPKDTINFLSKSVNRMKKSRLNDKQKHRLDFLQLMIDSQNSKETESHKALSDLELAAQSI
IFIFAGYETTSSVLSFTLYELATHPDVQQKLQKEIDAVLPNKAPPTYDAVVQMEYLDMVV
NETLRLFPVAIRLERTCKKDVEINGVFIPKGSMVVIPTYALHHDPKYWTEPEEFRPERFS
KKKDSIDPYIYTPFGTGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLDTQG
LLQPEKPIVLKVDSRDGTLSGE

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P20815

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
CYP2D6

# Phase_1_Metabolizing_Enzyme_2_ID:
4119

# Phase_1_Metabolizing_Enzyme_2_Name:
Cytochrome P450 2D6

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Cytochrome P450 2D6
MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYCFDQ
LRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVF
LARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDK
AVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVLLHIPALAGKV
LRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVA
DLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVI
HEVQRFGDIVPLGVTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHF
LDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGV
FAFLVSPSPYELCAVPR

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
P10635

# Phase_1_Metabolizing_Enzyme_3_Gene_Name:
CYP3A4

# Phase_1_Metabolizing_Enzyme_3_ID:
4512

# Phase_1_Metabolizing_Enzyme_3_Name:
Cytochrome P450 3A4

# Phase_1_Metabolizing_Enzyme_3_Protein_Sequence:
>Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA

# Phase_1_Metabolizing_Enzyme_3_SwissProt_ID:
P08684

# Phase_1_Metabolizing_Enzyme_4_Gene_Name:
CYP2C9

# Phase_1_Metabolizing_Enzyme_4_ID:
4757

# Phase_1_Metabolizing_Enzyme_4_Name:
Cytochrome P450 2C9

# Phase_1_Metabolizing_Enzyme_4_Protein_Sequence:
>Cytochrome P450 2C9
MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKV
YGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFM
KSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYID
LLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFK
KSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVP
PFYQLCFIPV

# Phase_1_Metabolizing_Enzyme_4_SwissProt_ID:
P11712

# Phase_1_Metabolizing_Enzyme_5_Gene_Name:
CYP2C8

# Phase_1_Metabolizing_Enzyme_5_ID:
4924

# Phase_1_Metabolizing_Enzyme_5_Name:
Cytochrome P450 2C8

# Phase_1_Metabolizing_Enzyme_5_Protein_Sequence:
>Cytochrome P450 2C8
MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDICKSFTNFSKV
YGPVFTVYFGMNPIVVFHGYEAVKEALIDNGEEFSGRGNSPISQRITKGLGIISSNGKRW
KEIRRFSLTTLRNFGMGKRSIEDRVQEEAHCLVEELRKTKASPCDPTFILGCAPCNVICS
VVFQKRFDYKDQNFLTLMKRFNENFRILNSPWIQVCNNFPLLIDCFPGTHNKVLKNVALT
RSYIREKVKEHQASLDVNNPRDFIDCFLIKMEQEKDNQKSEFNIENLVGTVADLFVAGTE
TTSTTLRYGLLLLLKHPEVTAKVQEEIDHVIGRHRSPCMQDRSHMPYTDAVVHEIQRYSD
LVPTGVPHAVTTDTKFRNYLIPKGTTIMALLTSVLHDDKEFPNPNIFDPGHFLDKNGNFK
KSDYFMPFSAGKRICAGEGLARMELFLFLTTILQNFNLKSVDDLKNLNTTAVTKGIVSLP
PSYQICFIPV

# Phase_1_Metabolizing_Enzyme_5_SwissProt_ID:
P10632

# Phase_1_Metabolizing_Enzyme_6_Gene_Name:
CYP2C19

# Phase_1_Metabolizing_Enzyme_6_ID:
6016

# Phase_1_Metabolizing_Enzyme_6_Name:
Cytochrome P450 2C19

# Phase_1_Metabolizing_Enzyme_6_Protein_Sequence:
>Cytochrome P450 2C19
MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDVSKSLTNLSKI
YGPVFTLYFGLERMVVLHGYEVVKEALIDLGEEFSGRGHFPLAERANRGFGIVFSNGKRW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFQKRFDYKDQQFLNLMEKLNENIRIVSTPWIQICNNFPTIIDYFPGTHNKLLKNLAFM
ESDILEKVKEHQESMDINNPRDFIDCFLIKMEKEKQNQQSEFTIENLVITAADLLGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVVGRNRSPCMQDRGHMPYTDAVVHEVQRYID
LIPTSLPHAVTCDVKFRNYLIPKGTTILTSLTSVLHDNKEFPNPEMFDPRHFLDEGGNFK
KSNYFMPFSAGKRICVGEGLARMELFLFLTFILQNFNLKSLIDPKDLDTTPVVNGFASVP
PFYQLCFIPV

# Phase_1_Metabolizing_Enzyme_6_SwissProt_ID:
P33261

# Phase_1_Metabolizing_Enzyme_7_Gene_Name:
CYP11A1

# Phase_1_Metabolizing_Enzyme_7_ID:
6017

# Phase_1_Metabolizing_Enzyme_7_Name:
Cholesterol side-chain cleavage enzyme, mitochondrial

# Phase_1_Metabolizing_Enzyme_7_Protein_Sequence:
>Cholesterol side-chain cleavage enzyme, mitochondrial
MLAKGLPPRSVLVKGCQTFLSAPREGLGRLRVPTGEGAGISTRSPRPFNEIPSPGDNGWL
NLYHFWRETGTHKVHLHHVQNFQKYGPIYREKLGNVESVYVIDPEDVALLFKSEGPNPER
FLIPPWVAYHQYYQRPIGVLLKKSAAWKKDRVALNQEVMAPEATKNFLPLLDAVSRDFVS
VLHRRIKKAGSGNYSGDISDDLFRFAFESITNVIFGERQGMLEEVVNPEAQRFIDAIYQM
FHTSVPMLNLPPDLFRLFRTKTWKDHVAAWDVIFSKADIYTQNFYWELRQKGSVHHDYRG
ILYRLLGDSKMSFEDIKANVTEMLAGGVDTTSMTLQWHLYEMARNLKVQDMLRAEVLAAR
HQAQGDMATMLQLVPLLKASIKETLRLHPISVTLQRYLVNDLVLRDYMIPAKTLVQVAIY
ALGREPTFFFDPENFDPTRWLSKDKNITYFRNLGFGWGVRQCLGRRIAELEMTIFLINML
ENFRVEIQHLSDVGTTFNLILMPEKPISFTFWPFNQEATQQ

# Phase_1_Metabolizing_Enzyme_7_SwissProt_ID:
P05108

# Phase_1_Metabolizing_Enzyme_8_Gene_Name:
CYP3A7

# Phase_1_Metabolizing_Enzyme_8_ID:
6107

# Phase_1_Metabolizing_Enzyme_8_Name:
Cytochrome P450 3A7

# Phase_1_Metabolizing_Enzyme_8_Protein_Sequence:
>Cytochrome P450 3A7
MDLIPNLAVETWLLLAVSLILLYLYGTRTHGLFKKLGIPGPTPLPFLGNALSFRKGYWTF
DMECYKKYRKVWGIYDCQQPMLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKNAISI
AEDEEWKRIRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKHVFGAYS
MDVITSTSFGVSIDSLNNPQDPFVENTKKLLRFNPLDPFVLSIKVFPFLTPILEALNITV
FPRKVISFLTKSVKQIKEGRLKETQKHRVDFLQLMIDSQNSKDSETHKALSDLELMAQSI
IFIFAGYETTSSVLSFIIYELATHPDVQQKVQKEIDTVLPNKAPPTYDTVLQLEYLDMVV
NETLRLFPVAMRLERVCKKDVEINGMFIPKGVVVMIPSYVLHHDPKYWREPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALVNMKLALVRVLQNFSFKPCKETQIPLKLRFG
GLLLTEKPIVLKAESRDETVSGA

# Phase_1_Metabolizing_Enzyme_8_SwissProt_ID:
P24462

# Drug_Target_1_Cellular_Location:
Cytoplasmic

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
17638694	Dandache S, Sevigny G, Yelle J, Stranix BR, Parkin N, Schapiro JM, Wainberg MA, Wu JJ: In Vitro Antiviral Activity and Cross-Resistance Profile of PL-100, a Next Generation Protease Inhibitor of Human Immunodeficiency Virus Type 1. Antimicrob Agents Chemother. 2007 Jul 16;.
17849388	Wittayanarakul K, Hannongbua S, Feig M: Accurate prediction of protonation state as a prerequisite for reliable MM-PB(GB)SA binding free energy calculations of HIV-1 protease inhibitors. J Comput Chem. 2007 Sep 11;.
19040279	Dandache S, Coburn CA, Oliveira M, Allison TJ, Holloway MK, Wu JJ, Stranix BR, Panchal C, Wainberg MA, Vacca JP: PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study. J Med Virol. 2008 Dec;80(12):2053-63.
19537723	Alcaro S, Artese A, Ceccherini-Silberstein F, Ortuso F, Perno CF, Sing T, Svicher V: Molecular dynamics and free energy studies on the wild-type and mutated HIV-1 protease complexed with four approved drugs: mechanism of binding and drug resistance. J Chem Inf Model. 2009 Jul;49(7):1751-61.
20660676	Rhee SY, Taylor J, Fessel WJ, Kaufman D, Towner W, Troia P, Ruane P, Hellinger J, Shirvani V, Zolopa A, Shafer RW: HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrob Agents Chemother. 2010 Oct;54(10):4253-61. Epub 2010 Jul 26.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
AJ010714

# Drug_Target_1_GenBank_ID_Protein:
4377614

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
HIV-1 protease

# Drug_Target_1_Gene_Sequence:
>297 bp
CCTCAGGTCACTCTTTGGCAACGACCCATAGTCACAATAAAGATAGGGGGGCAACTAAAG
GAAGCTCTATTAGATACAGGAGCAGATGATACAGTATTAGAAGAAATGAGTTTGCCAGGA
AAATGGAAACCAAAAATGATAGGGGGAATTGGAGGTTTTATCAAAGTAAGACAGTATGAT
CAGGTATCCATAGAAATCTGCGGACATAAAGCTATAGGTACAGTATTAATAGGACCTACA
CCTGTCAACATAATTGGAAGGAATCTGTTGACTCAGCTTGGCTGCACTTTAAATTTT

# Drug_Target_1_General_Function:
Involved in aspartic-type endopeptidase activity

# Drug_Target_1_General_References:
11158089	Servais J, Lambert C, Fontaine E, Plesseria JM, Robert I, Arendt V, Staub T, Schneider F, Hemmer R, Burtonboy G, Schmit JC: Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy. J Clin Microbiol. 2001 Feb;39(2):454-9.
11181376	Servais J, Lambert C, Fontaine E, Plesseria JM, Robert I, Arendt V, Staub T, Schneider F, Hemmer R, Burtonboy G, Schmit JC: Variant human immunodeficiency virus type 1 proteases and response to combination therapy including a protease inhibitor. Antimicrob Agents Chemother. 2001 Mar;45(3):893-900.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
731

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
10725

# Drug_Target_1_Name:
HIV-1 protease

# Drug_Target_1_Number_of_Residues:
99

# Drug_Target_1_PDB_ID:
1ODW

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00077	RVP

# Drug_Target_1_Protein_Sequence:
>HIV-1 protease
PQVTLWQRPIVTIKIGGQLKEALLDTGADDTVLEEMSLPGKWKPKMIGGIGGFIKVRQYD
QVSIEICGHKAIGTVLIGPTPVNIIGRNLLTQLGCTLNF

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
O90777

# Drug_Target_1_SwissProt_Name:
O90777_9PLVG

# Drug_Target_1_Synonyms:
Fragment

# Drug_Target_1_Theoretical_pI:
8.77

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB01232
